VANGUARD GROUP INC 13D and 13G filings for Travere Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 1:33 pm Sale | 2026-03-13 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 0 0.000% | -5,994,283 (Position Closed) | Filing |
| 2025-07-29 2:41 pm Purchase | 2025-06-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 5,994,283 6.740% | 980,263 (+19.55%) | Filing |
| 2025-04-30 11:22 am Sale | 2025-03-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 5,014,020 5.650% | -1,728,145 (-25.63%) | Filing |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 6,742,165 7.750% | -159,985 (-2.32%) | Filing |
| 2024-11-12 5:56 pm Unchanged | 2024-09-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 6,902,150 9.020% | 0 (Unchanged) | Filing |
| 2024-11-04 1:55 pm Purchase | 2024-09-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 6,902,150 9.020% | 1,387,007 (+25.15%) | Filing |
| 2024-02-13 5:16 pm Purchase | 2023-12-29 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 5,515,143 7.340% | 1,999,697 (+56.88%) | Filing |
| 2023-02-09 11:35 am Sale | 2022-12-30 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 3,515,446 5.480% | -365,427 (-9.42%) | Filing |
| 2022-02-10 08:42 am Purchase | 2021-12-31 | 13G | TRAVERE THERAPEUTICS INC TVTX | VANGUARD GROUP INC | 3,880,873 6.340% | 476,430 (+13.99%) | Filing |